And any pipeline setback would likely cause Iovance's share price to plunge. So could Iovance Biotherapeutics be a millionaire-maker? I think the best answer is...maybe. Iovance should have a lot ...

Barclays lowered the firm’s price target on Iovance Biotherapeutics (IOVA) to $5 from $22 and keeps an Overweight rating on the shares as part of a Q1 earnings preview. The firm says its survey ...

It’s the latest in a series of violent incidents and police activity at Sonoma County schools during the current academic year.

Sonoma County officials blasted Avelo Airlines’ decision to shutter its operations base at the county’s regional airport to divert resources to Arizona, where the company will provide ...

Dave Pehling is website managing editor for CBS Bay Area. He started his journalism career doing freelance writing about music in the late 1990s, eventually working as a web writer, editor and ...

Missy Elliott brought her futuristic visual style to the Coachella stage and went full Transformers in a robotics-themed performance. As spotted on TMZ, Missy Elliott was among the dozens of high ...

Missy Elliott brought the supersized vision from last year’s “Out of This World” tour to Coachella on Friday night, performing a sizzling — if not almost exact — set rife with dancing ...

Littman is a co-founder of Vendanta Biosciences and ImmunAI, and serves on the advisory boards of IMIDomics, Sonoma Biotherapeutics, NILO Therapeutics, and Evommune, and on the board of directors ...

I know that this could be the answer for so many people out there." Creative BioTherapeutics is poised to lead the way, but it needs the support of investors, healthcare advocates, and the global ...

In a report released on March 28, Francois Brisebois from Oppenheimer maintained a Buy rating on Sensei Biotherapeutics (SNSE – Research Report), with a price target of $4.00. The company’s ...

Littman is a co-founder of Vendanta Biosciences and ImmunAI, and serves on the advisory boards of IMIDomics, Sonoma Biotherapeutics, NILO Therapeutics, and Evommune, and on the board of directors ...